The aim of this analysis was to evaluate the efficacy of sofosbuvir/velpatasvir/voxipalrevir (SVV) and glecaprevir/pibrentavir + sofosbuvir (GPS) among vulnerable populations such as PWID.
Real-world efficacy of salvage therapies for the treatment of chronic hepatitis C virus infection in treatment experienced people who inject drugs (PWID)First presented at the American Association of the Study of Liver Diseases, November 8-12, Boston, U.S.A, 2019.